Global Car T Cell Therapy Market Research Report Forecast to 2025
|発行||Market Research Future||商品コード||913700|
|出版日||ページ情報||英文 79 Pages
|世界のCAR-T細胞療法市場：2025年までの予測 Global Car T Cell Therapy Market Research Report Forecast to 2025|
|出版日: 2019年09月30日||ページ情報: 英文 79 Pages||
CAR T Cell Therapy Market Research Report - Global Forecast till 2025
Global CAR T Cell Therapy Market: Information by Target Antigen (CD19, CD22 and others), Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma and others) and Region - Forecast till 2025
The Global CAR T Cell Therapy Market is anticipated to register a CAGR of 58.52% to attain USD 8716.06 Million by the year 2025. Chimeric Antigen Receptor (CAR) T Cell Therapy is an immunotherapy that is used for cancer treatment. In this therapy, T cells from patient body are separated and introduced in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient's cancer cells. The rising incidence of cancer across the world, technological advancement for advanced & reliable treatment for cancer, growing pharmaceutical industry, and growth in the number of cell therapy clinical studies are pushing the growth of the global CAR T cell therapy market. However, side-effects of CAR T-cell therapy and high cost of treatment are likely to hinder the market growth. Growing frequency of cancer across the world, technological progress for advanced & reliable treatment for cancer, and increase in the number of cell therapy clinical studies are pushing the growth of the global CAR T cell therapy market. According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018. Moreover, the growing pharmaceutical industry is also expected to boost market growth. One of the main strategies followed by players operating in the global CAR T cell therapy market were innovation, product growth, and acquisitions & mergers. In April 2019, Autolus Therapeutics PLC was granted with an orphan drug designation, to autologous improved T-cells, inherently altered with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 (AUTO3) for the treatment of severe lymphoblastic leukemia (ALL), by the US FDA.
Global CAR T Cell Therapy Market has been segmented by Target Antigen, by application, and by region. Based on target antigen the market has been split into CD19, CD22, and Others. Based on application, the global CAR T Cell Therapy Market has been divided into Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma and Others. On the basis of region, the global CAR T Cell Therapy Market, by Region has been segmented US, Europe, China and Rest of the World
Geographically the global CAR T cell therapy market is split in regions like US, Europe, China, and the RoW. the major share of the global CAR T cell therapy market is expected to be held by US. This is owed to the growing cases of cancer in the country. Europe showed a significant amount of development in the market due to rise in the incidences of hematologic cancer such as leukemia, lymphoma, and multiple myeloma. Europe held a market share of 9.15% in the global CAR T cell therapy market. China is projected to substantially increase in the global market due to the emerging healthcare infrastructure and rising disposable income. Also, the market in the Middle East & Africa is projected to show the least growth owing to limited healthcare access and affordability among the population.
The proposed spectators in the global CAR T cell therapy market are Hospitals, Pharmaceutical companies, Biotechnology Companies, Research institutes, Contract Research Organizations, Academic institutes. The major companies functioning in the global CAR T cell therapy market are concentrating on firming their global ways by entering into untouched markets. Pfizer, Inc. (US), Kite Pharma (US), Cellectis (France), Autolus Therapeutics PLC (UK), uno Therapeutics (US), Sorrento Therapeutics (US), (US), Mustang Bio (US), Novartis AG (Switzerland), CARsgen Therapeutics (China), Legend Biotech and others are some of the prominent players in the global CAR T cell therapy market.